A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.

Detalles Bibliográficos
Autores principales: Broccoli, Alessandro, Argnani, Lisa, Cross, Matthew, Janus, Agnieszka, Maitre, Elsa, Troussard, Xavier, Robak, Tadeusz, Dearden, Claire, Else, Monica, Catovsky, Daniel, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327549/
https://www.ncbi.nlm.nih.gov/pubmed/35584397
http://dx.doi.org/10.1182/bloodadvances.2022007854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327549/
https://www.ncbi.nlm.nih.gov/pubmed/35584397
http://dx.doi.org/10.1182/bloodadvances.2022007854

Ejemplares similares